Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04269200 · ClinicalTrials.gov registry record · Phase 3

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

A Phase 3 study of Endometrial Neoplasms, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
805
Enrollment target
20
Study locations

NCT04269200 is a Phase 3 study of Endometrial Neoplasms that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 805 participants, above the 319-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (152% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04269200, a Phase 3 study of Endometrial Neoplasms, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
805 participants
Enrollment target
20
Study locations

Study Summary

A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

Conditions Studied

Endometrial Neoplasms

Interventions

  • DRUG Carboplatin
  • DRUG olaparib
  • BIOLOGICAL durvalumab
  • DRUG durvalumab placebo
  • DRUG olaparib placebo

Study Locations (20)

California

  • Research Site - Concord
  • Research Site - La Jolla
  • Research Site - San Francisco
  • Research Site - Santa Barbara

Florida

  • Research Site - Fort Lauderdale
  • Research Site - Tampa

Illinois

  • Research Site - Arlington Heights
  • Research Site - Chicago

Arizona

  • Research Site - Tucson

Colorado

  • Research Site - Aurora

Georgia

  • Research Site - Savannah

Hawaii

  • Research Site - Honolulu

Indiana

  • Research Site - Indianapolis

Trial Details

FieldValue
Enrollment Target 805 participants
Start Date 2020-05-05
Est. Completion 2027-04-01
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04269200

The ClinicalTrials.gov registry entry for NCT04269200 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 805 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 319-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (152% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT04269200 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT04269200 about?

NCT04269200 is a clinical study titled "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer". A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.

What is the current status of trial NCT04269200?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 805 participants. The study started on 2020-05-05. Estimated completion is 2027-04-01.

What conditions does trial NCT04269200 study?

This clinical trial studies the following conditions: Endometrial Neoplasms.

What interventions are being tested in trial NCT04269200?

The interventions under investigation include: Carboplatin (DRUG), olaparib (DRUG), durvalumab (BIOLOGICAL), durvalumab placebo (DRUG), olaparib placebo (DRUG).

Who is sponsoring clinical trial NCT04269200?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04269200 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Neoplasms

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.